Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | NAAA | Q02083 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2936706 | 0.88 | THRB (0.52) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL22280824 | 0.86 | TSHR (0.58) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL5872182 | 0.86 | TSHR (0.58) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL18403041 | 0.86 | TSHR (0.58) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL14980 | 0.85 | TSHR (0.56) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL22977907 | 0.83 | TSHR (0.55) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL444306 | 0.83 | TSHR (0.55) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL20970602 | 0.83 | TSHR (0.55) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL219271 | 0.83 | TSHR (0.55) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL23607561 | 0.83 | TSHR (0.55) | TSHRTHRBPOLBAPEX1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4124331-A1 | AESTHETIC DENTAL FILLING MATERIAL WITH HIGH CURING DEPTH | Ivoclar Vivadent AG (LI) | 2023-02-01 | — | — | EP | claimed |
| US-9851639-B2 | Photoacid generating polymers containing a urethane linkage for lithography | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2017-12-26 | — | — | US | disclosed |
| US-9254255-B2 | Dental care product with two-part formulations and utility thereof | CHUNG-YUAN CHRISTIAN UNIVERSITY (TW) | 2016-02-09 | — | — | US | disclosed |
| US-20150150781-A1 | Dental Care Product with Two-part Formulations and Utility Thereof | CHUNG-YUAN CHRISTIAN UNIVERSITY (TW) | 2015-06-04 | — | — | US | disclosed |
| US-20130260313-A1 | PHOTOACID GENERATING POLYMERS CONTAINING A URETHANE LINKAGE FOR LITHOGRAPHY | CENTRAL GLASS CO., LTD. (JP) | 2013-10-03 | — | — | US | disclosed |
| US-20120121687-A1 | Wound healing material and method for fabricating the same | CHUNG YUAN CHRISTIAN UNIVERSITY (TW) | 2012-05-17 | — | — | US | disclosed |
| US-20120067821-A1 | Filter Medium For Leukocyte Removal | CHUNG YUAN CHRISTIAN UNIVERSITY (TW) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150150781-A1 | Dental Care Product with Two-part Formulations and Utility Thereof | KRTCAP2, DDOST, STT3B | TSHR 3436/4885THRB 1422/4885POLB 123/4885 |
| US-20120121687-A1 | Wound healing material and method for fabricating the same | FGB, FIBP, FLNA | TSHR 4123/4885THRB 4683/4885POLB 2797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.